Viking Therapeutics, Inc. (FRA:1VT)

Viking Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-237.39	-109.96	-85.9	-68.87	-54.99	-39.5
Depreciation & Amortization	0.45	0.35	0.29	0.29	0.3	0.28
Other Amortization	0.08	0.09	0.09	0.06	0.02	0.11
Loss (Gain) From Sale of Investments	-11.6	-17.38	-8.2	1.22	3.91	3.77
Stock-Based Compensation	37.9	29.71	16.75	8.67	6.1	5.82
Other Operating Activities	0.04	0.04	0.04	0.04	0.01	0.03
Change in Accounts Payable	4.16	2.3	-1.02	7.09	-2.54	1.56
Change in Other Net Operating Assets	-18.21	7.06	4.57	3.1	-0.38	6.16
Operating Cash Flow	-224.58	-87.79	-73.38	-48.4	-47.59	-21.78
Investment in Securities	272.36	-553.37	-179.09	54.75	37.96	41.57
Investing Cash Flow	272.36	-553.37	-179.09	54.75	37.96	41.57
Issuance of Common Stock	2.34	654.57	278.5	12.51	7.63	1.27
Repurchase of Common Stock	-	-42.1	-7.12	-8.33	-0.71	-0.3
Other Financing Activities	-	-	-	-0.02	-0.05	-0.03
Financing Cash Flow	2.34	612.46	271.38	4.16	6.88	0.95
Foreign Exchange Rate Adjustments	-0.09	-0.15	-0.03	-0.26	-	-
Net Cash Flow	50.03	-28.84	18.88	10.26	-2.75	20.74
Levered Free Cash Flow	-150.9	-55.58	-42.36	-25.22	-32.16	-15.06
Unlevered Free Cash Flow	-150.93	-55.61	-42.4	-25.24	-32.16	-15.1
Change in Working Capital	-14.05	9.36	3.55	10.19	-2.93	7.72

Source: S&P Global Market Intelligence. Standard template. Financial Sources.